Tempest Therapeutics Inc

Company Profile

Tempest Therapeutics Inc had its IPO on 2012-11-12 under the ticker symbol TPST.

The company operates in the Healthcare sector and Biotechnology industry. Tempest Therapeutics Inc has a staff strength of 19 employees.

Stock update

Shares of Tempest Therapeutics Inc opened at $0.44 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.44 - $0.58, and closed at $0.57.

This is a +30.14% increase from the previous day's closing price.

A total volume of 504,466 shares were traded at the close of the day’s session.

In the last one week, shares of Tempest Therapeutics Inc have increased by +5.56%.

Tempest Therapeutics Inc's Key Ratios

Tempest Therapeutics Inc has a market cap of $7.20 million, indicating a price to book ratio of 0.6148 and a price to sales ratio of 0.

In the last 12-months Tempest Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-32130000. The EBITDA ratio measures Tempest Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Tempest Therapeutics Inc’s operating margin was 0% while its return on assets stood at -40.11% with a return of equity of -166.57%.

In Q2, Tempest Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Tempest Therapeutics Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-2.16 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Tempest Therapeutics Inc’s profitability.

Tempest Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.2975. Its price to sales ratio in the trailing 12-months stood at 0.

Tempest Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$30.74 million

Total Liabilities

$8.64 million

Operating Cash Flow

$0

Capital Expenditure

$117000

Dividend Payout Ratio

0%

Tempest Therapeutics Inc ended 2024 with $30.74 million in total assets and $0 in total liabilities. Its intangible assets were valued at $30.74 million while shareholder equity stood at $5.01 million.

Tempest Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $8.64 million in other current liabilities, 13000.00 in common stock, $-150989000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $17.60 million and cash and short-term investments were $17.60 million. The company’s total short-term debt was $4,388,000 while long-term debt stood at $7.48 million.

Tempest Therapeutics Inc’s total current assets stands at $18.54 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $868000.00 and inventory worth $0.

In 2024, Tempest Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $117000.

Comparatively, Tempest Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0.57

52-Week High

$4.214

52-Week Low

$0.39

Analyst Target Price

$15.67

Tempest Therapeutics Inc stock is currently trading at $0.57 per share. It touched a 52-week high of $4.214 and a 52-week low of $4.214. Analysts tracking the stock have a 12-month average target price of $15.67.

Its 50-day moving average was $0.82 and 200-day moving average was $1.52 The short ratio stood at 0.1 indicating a short percent outstanding of 0%.

Around 300% of the company’s stock are held by insiders while 6891.7% are held by institutions.